CytomX Therapeutics (CTMX) IPO Prices at $12, Below Expected Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
CytomX Therapeutics (CTMX) IPO Opens Sharply Higher, Pares Gains
October 8, 2015 2:49 PM EDTToday's IPO for CytomX Therapeutics, Inc. (NASDAQ: CTMX) opened for trading earlier at $16 after pricing 6,666,667 shares of common stock at an initial public offering price of $12 per share, below the $14-$16 range. Shares have since backed down to $14.35.
In addition, the underwriters have a 30-day option to purchase up to an additional 1,000,000 shares of common stock from CytomX. All shares of common stock are being offered by CytomX.
BofA Merrill Lynch, Jefferies LLC and Cowen and... More
